Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome

Luis Alberto Castillo-Díaz,1 Juan Alberto Ruiz-Pacheco,2 Mohamed Ahmed Elsawy,3 Juana Elizabeth Reyes-Martínez,4 Andrea Isabel Enríquez-Rodríguez1 1Department of Medicine and Health Sciences, University of Sonora, Hermosillo, Sonora, Mexico; 2West Biomedic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Castillo-Díaz LA, Ruiz-Pacheco JA, Elsawy MA, Reyes-Martínez JE, Enríquez-Rodríguez AI
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	peptide hydrogel nanomaterials metabolic syndrome diabetes obesity cardiovascular disease Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c97c5d02ce5f4dd5bcfcb1f579f750c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c97c5d02ce5f4dd5bcfcb1f579f750c3
record_format	dspace
spelling	oai:doaj.org-article:c97c5d02ce5f4dd5bcfcb1f579f750c32021-12-02T10:34:29ZSelf-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome1178-2013https://doaj.org/article/c97c5d02ce5f4dd5bcfcb1f579f750c32020-12-01T00:00:00Zhttps://www.dovepress.com/self-assembling-peptides-as-an-emerging-platform-for-the-treatment-of--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Luis Alberto Castillo-Díaz,1 Juan Alberto Ruiz-Pacheco,2 Mohamed Ahmed Elsawy,3 Juana Elizabeth Reyes-Martínez,4 Andrea Isabel Enríquez-Rodríguez1 1Department of Medicine and Health Sciences, University of Sonora, Hermosillo, Sonora, Mexico; 2West Biomedical Research Center, National Council of Science and Technology, Guadalajara, Jalisco, Mexico; 3Leicester Institute for Pharmaceutical Innovation, Leicester School of Pharmacy, De Montfort University, Leicester, Leicestershire, UK; 4Department of Biology, University of Guanajuato, Guanajuato, Guanajuato, MexicoCorrespondence: Luis Alberto Castillo-DíazDepartment of Medicine and Health Sciences, University of Sonora, Hermosillo, Sonora 83000, MexicoTel +52 662 2592121Ext. 4593 Email luis.castillo@unison.mxAbstract: Metabolic syndrome comprises a cluster of comorbidities that represent a major risk of developing chronic diseases, such as type II diabetes, cardiovascular diseases, and stroke. Alarmingly, metabolic syndrome reaches epidemic proportions worldwide. Today, lifestyle changes and multiple drug-based therapies represent the gold standard to address metabolic syndrome. However, such approaches face two major limitations: complicated drug therapeutic regimes, which in most cases could lead to patient incompliance, and limited drug efficacy. This has encouraged scientists to search for novel routes to deal with metabolic syndrome and related diseases. Within such approaches, self-assembled peptide formulations have emerged as a promising alternative for treating metabolic syndrome. In particular, self-assembled peptide hydrogels, either as acellular or cell-load three-dimensional scaffoldings have reached significant relevance in the biomedical field to prevent and restore euglycemia, as well as for controlling cardiovascular diseases and obesity. This has been possible thanks to the physicochemical tunability of peptides, which are developed from a chemical toolbox of versatile amino acids enabling flexibility of designing a wide range of self-assembled/co-assembled nanostructures forming biocompatible viscoelastic hydrogels. Peptide hydrogels can be combined with several biological entities, such as extracellular matrix proteins, drugs or cells, forming functional biologics with therapeutic ability for treatment of metabolic syndrome-comorbidities. Additionally, self-assembly peptides combine safety, tolerability, and effectivity attributes; by this presenting a promising platform for the development of novel pharmaceuticals capable of addressing unmet therapeutic needs for diabetes, cardiovascular disorders and obesity. In this review, recent advances in developing self-assembly peptide nanostructures tailored for improving treatment of metabolic syndrome and related diseases will be discussed from basic research to preclinical research studies. Challenges facing the development of approved medicinal products based on self-assembling peptide nanomaterials will be discussed in light of regulatory requirement for clinical authorization.Keywords: peptide, hydrogel, nanomaterials, metabolic syndrome, diabetes, obesity, cardiovascular diseaseCastillo-Díaz LARuiz-Pacheco JAElsawy MAReyes-Martínez JEEnríquez-Rodríguez AIDove Medical Pressarticlepeptidehydrogelnanomaterialsmetabolic syndromediabetesobesitycardiovascular diseaseMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 10349-10370 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	peptide hydrogel nanomaterials metabolic syndrome diabetes obesity cardiovascular disease Medicine (General) R5-920
spellingShingle	peptide hydrogel nanomaterials metabolic syndrome diabetes obesity cardiovascular disease Medicine (General) R5-920 Castillo-Díaz LA Ruiz-Pacheco JA Elsawy MA Reyes-Martínez JE Enríquez-Rodríguez AI Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
description	Luis Alberto Castillo-Díaz,1 Juan Alberto Ruiz-Pacheco,2 Mohamed Ahmed Elsawy,3 Juana Elizabeth Reyes-Martínez,4 Andrea Isabel Enríquez-Rodríguez1 1Department of Medicine and Health Sciences, University of Sonora, Hermosillo, Sonora, Mexico; 2West Biomedical Research Center, National Council of Science and Technology, Guadalajara, Jalisco, Mexico; 3Leicester Institute for Pharmaceutical Innovation, Leicester School of Pharmacy, De Montfort University, Leicester, Leicestershire, UK; 4Department of Biology, University of Guanajuato, Guanajuato, Guanajuato, MexicoCorrespondence: Luis Alberto Castillo-DíazDepartment of Medicine and Health Sciences, University of Sonora, Hermosillo, Sonora 83000, MexicoTel +52 662 2592121Ext. 4593 Email luis.castillo@unison.mxAbstract: Metabolic syndrome comprises a cluster of comorbidities that represent a major risk of developing chronic diseases, such as type II diabetes, cardiovascular diseases, and stroke. Alarmingly, metabolic syndrome reaches epidemic proportions worldwide. Today, lifestyle changes and multiple drug-based therapies represent the gold standard to address metabolic syndrome. However, such approaches face two major limitations: complicated drug therapeutic regimes, which in most cases could lead to patient incompliance, and limited drug efficacy. This has encouraged scientists to search for novel routes to deal with metabolic syndrome and related diseases. Within such approaches, self-assembled peptide formulations have emerged as a promising alternative for treating metabolic syndrome. In particular, self-assembled peptide hydrogels, either as acellular or cell-load three-dimensional scaffoldings have reached significant relevance in the biomedical field to prevent and restore euglycemia, as well as for controlling cardiovascular diseases and obesity. This has been possible thanks to the physicochemical tunability of peptides, which are developed from a chemical toolbox of versatile amino acids enabling flexibility of designing a wide range of self-assembled/co-assembled nanostructures forming biocompatible viscoelastic hydrogels. Peptide hydrogels can be combined with several biological entities, such as extracellular matrix proteins, drugs or cells, forming functional biologics with therapeutic ability for treatment of metabolic syndrome-comorbidities. Additionally, self-assembly peptides combine safety, tolerability, and effectivity attributes; by this presenting a promising platform for the development of novel pharmaceuticals capable of addressing unmet therapeutic needs for diabetes, cardiovascular disorders and obesity. In this review, recent advances in developing self-assembly peptide nanostructures tailored for improving treatment of metabolic syndrome and related diseases will be discussed from basic research to preclinical research studies. Challenges facing the development of approved medicinal products based on self-assembling peptide nanomaterials will be discussed in light of regulatory requirement for clinical authorization.Keywords: peptide, hydrogel, nanomaterials, metabolic syndrome, diabetes, obesity, cardiovascular disease
format	article
author	Castillo-Díaz LA Ruiz-Pacheco JA Elsawy MA Reyes-Martínez JE Enríquez-Rodríguez AI
author_facet	Castillo-Díaz LA Ruiz-Pacheco JA Elsawy MA Reyes-Martínez JE Enríquez-Rodríguez AI
author_sort	Castillo-Díaz LA
title	Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_short	Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_full	Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_fullStr	Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_full_unstemmed	Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome
title_sort	self-assembling peptides as an emerging platform for the treatment of metabolic syndrome
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/c97c5d02ce5f4dd5bcfcb1f579f750c3
work_keys_str_mv	AT castillodiazla selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome AT ruizpachecoja selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome AT elsawyma selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome AT reyesmartinezje selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome AT enriquezrodriguezai selfassemblingpeptidesasanemergingplatformforthetreatmentofmetabolicsyndrome
_version_	1718397025897152512

Self-Assembling Peptides as an Emerging Platform for the Treatment of Metabolic Syndrome

Ejemplares similares